Skip to content
value.today
Kite Pharma, Inc. logo

Kite Pharma, Inc.

Total raised
$29 M
2 rounds on record
Latest round
$16 M
May 2013
First round on record
Feb 2011
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Kite Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2013$16 MNo. 2$10 to $50 million

Kite Pharma, Inc.: Raise no. 2, May 2013

Investors in this round

31 investors had bought by the notice of May 24, 2013: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Kite Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aya Jakobovits · Executive Officer, Director
  • Arie S. Belldegrun · Director
  • David A. Bonderman · Director
  • Farah B. Champsi · Director
  • Joshua A. Kazam · Director
  • Ran B. Nussbaum · Director
  • Roy B. Doumani · Director
  • Steven B. Ruchefsky · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Aya Jakobovits, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 24, 2013. Read the notice at the SEC.

equitySEC
Feb 2011$12 MNo. 1$10 to $50 million

Kite Pharma, Inc.: Raise no. 1, Feb 2011

Investors in this round

40 investors had bought by the notice of Mar 9, 2011: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Kite Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $13 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$554,548
Finders' fees
none
Paid to its own people
$600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aya Jakobovits · Executive Officer, Director
  • Gloria S. Lee · Executive Officer
  • Arie S. Belldegrun · Director
  • David A. Bonderman · Director
  • Joshua A. Kazam · Director
  • Steven B. Ruchefsky · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Riverbank Capital Securities, Inc. (CRD 135310) · broker-dealer Riverbank Capital Securities, Inc. (CRD 135310) · New York, New YorkSold in AZ, CA, CO, CT, DC, DE, FL, IL, MA, MD, MI, NC, NJ, NY, OH, PA, TX, VA, WA, and outside the US

Remarks in the notice

  • On fees: “Riverbank will also be reimbursed for expenses of up to $50k. Also, upon a future financing, Riverbank will receive warrants to purchase an amount of securities equal to 5% of the securities into which the notes held by certain investors are converted.”
  • On the use of proceeds: “Represents amounts payable as salary to the Issuer's executive officers over the next 12 months.”

Signed by Aya Jakobovits, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 9, 2011. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kite Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (May 2013).

    SEC Form D · May 2013

  • It delivers 1 product named in the sources below.

    See Products and services

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2013

In its own words

How the company describes itself to search engines on its website, word for word.

“Kite is dedicated to curing cancer. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline.”

Source: The company's website · as of Nov 15, 2026

Products#

1 named by the sources below.

  • cancer immunotherapy

    Wikidata · Wikidata: product or material produced (P1056)

Services#

No services of Kite Pharma, Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Kite Pharma, Inc.
InvestorKindAmountRoundRoleSource
Roy DoumaniPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 40 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kite Pharma, Inc.
NameRoleNamed in
Aya JakobovitsExecutive officerMay 2013
Gloria S. LeeExecutive officerMar 2011
Arie S. BelldegrunDirectorMay 2013
Aya JakobovitsDirectorMay 2013
David A. BondermanDirectorMay 2013
Farah B. ChampsiDirectorMay 2013
Joshua A. KazamDirectorMay 2013
Ran B. NussbaumDirectorMay 2013
Roy B. DoumaniDirectorMay 2013
Steven B. RuchefskyDirectorMay 2013

About

Biomedical engineering company that develops cancer immunotherapy products.